NextCure Inc (NXTC)
NASDAQ:NXTC
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$3.49 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$41.44M
Enterprise Value$12.19M
Total Cash (Recent Filing)$41.82M
Total Debt (Recent Filing)$5.15M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Apr 30, 2026EPS Estimate
-1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding3,560,410
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.38
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advancing ADC Clinical ProgramsAdvancing two ADC programs through Phase 1 dose-escalation (SIM0505 and LNCB74) creates durable R&D value drivers: upcoming SIM0505 data and broader enrollment for LNCB74 can materially de-risk assets, enable partnering/licensing opportunities, and support long-term pipeline value if signals are positive.
Low Financial LeverageModest debt and a low debt-to-equity ratio reduce bankruptcy and interest burden risk, giving management more flexibility to fund clinical development via equity or partnerships rather than servicing heavy debt. This structural balance-sheet strength supports sustained R&D focus over the medium term.
Cash Runway Through Clinical InflectionA reported cash runway into 1H 2027 provides time to hit near-term clinical milestones (SIM0505 data in Q2 2026, LNCB74 updates later in 2026). This runway reduces immediate financing pressure and allows the company to generate more definitive data that can materially improve strategic options.
Bears Say
Pre-revenue, Persistent LossesThe company remains pre-revenue with substantial recurring net losses, meaning sustainable operations depend on external capital. Persistent negative profitability limits reinvestment capacity and increases long-term execution risk if clinical programs do not produce value-driving outcomes.
Severe Equity Dilution TrendA sharp decline in shareholders' equity over several years reflects repeated financing and accumulated deficits; structurally this raises dilution risk for existing holders and can constrain the company's ability to raise future capital on favorable terms, affecting long-term shareholder value.
Ongoing High Cash BurnConsistent ~-$50M annual cash burn creates a structural dependence on financing programs (equity offerings, partnerships). This persistent outflow forces management to allocate time to fundraising, may dilute R&D investment flexibility, and elevates execution risk if capital markets tighten.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $3.49 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $41.44M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Mar 05, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$2.29 by $1.83.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Overvalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.83.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,560,410 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$2.29. Following the earnings report the stock price went down -2.9%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.18%
12-Months-Change
Fundamentals
Return on Equity
-152.90%
Trailing 12-Months
Asset Growth
-37.65%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Technical Analysis
Ownership Overview
―
Insiders
7.73% Mutual Funds
44.77% Other Institutional Investors
44.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---